Clinical Trial

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-18
notable Primary completion pushed: 2029-05-01 -> 2029-06-11 2026-06-18
minor Completion pushed: 2030-05-01 -> 2030-06-11 2026-06-18
Trial Details
NCT Number NCT07541781
Lead Sponsor Kailin Yang, MD, PhD
Conditions Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder)
Enrollment 45 participants
Start Date 2026-06-11
Primary Completion 2029-06-11 (estimated)
Study Completion 2030-06-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-17